Should You Buy UiPath Stock Before the Huge Investor Update? | PATH Stock Analysis
Summary
Parkev analyzes UiPath's financial trajectory, noting that revenue has grown to $1.67 billion from $400 million in 2020. Parkev emphasizes the dramatic improvement in operating profit margins, which moved from negative 150% to positive 6.3% in the most recent trailing twelve-month period. Parkev also points to the return on invested capital of 16.91% as a sign of financial health, which now exceeds the company's weighted average cost of capital.
Parkev addresses the primary risk to the investment thesis: the threat of agentic AI and proprietary automation solutions replacing traditional robotic process automation. Parkev observes that while this risk remains a concern for investors, UiPath is currently defending its market share and utilizing its own AI enhancements to secure new customer contracts. Parkev calculates an intrinsic value of $18.64 per share using a updated discounted cash flow model, which compares favorably to the recent market price of $15.83.
Mentioned Stocks
Reasoning: Parkev believes UiPath is undervalued with a forward P/E of 17.5 and an intrinsic value of $18.64, representing a 17.75% upside from the price of $15.83. Parkev points to the successful return of founder Daniel Dines and a healthy 17% revenue growth as key drivers. However, Parkev advises waiting until after the September 3rd earnings report to buy, as any sign of revenue deceleration could lead to a significant price drop due to fears over AI competition.